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Take home message 
Evaluation of treatment effect durability over time cannot be based on analyses that examine the 
first of many events. Here, we explain how misinterpretation of survival curves led to wrong 
conclusions in the recent Suissa and Ariel’s editorial [1]. 
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To the Editor: 
Great care should be taken when assessing the consistency of treatment effect over time based on a 
survival curve plot, and even more so when a treatment affects a repeating event endpoint such as 
exacerbations rather than an event that can occur only once, like death. 
In their recent editorial in this journal [1], Suissa and Ariel make the assertation that survival 
functions plotted from Kaplan-Meier estimates from Figure 1b in the IMPACT study [2] “clearly show 
that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-
up is due to the first-month’s surge, with practically no differences in the subsequent rates between 
the two groups”. However, this statement is based on a misunderstanding of the survival analyses 
presented. 
The events plotted on the figure are the first moderate or severe COPD exacerbations experienced 
by a patient in the IMPACT study. Suissa and Ariel’s statements about exacerbation rates refer to the 
rate of first exacerbations only, and not to the rate of all exacerbations during the study.  
Their conclusion that the rates of first exacerbations, and ratio between those rates changes over 
time is correct. However, this is entirely in line with statistical theory for repeated events with 
overall constant rates. It cannot be used to support any conclusion that the difference in the rate of 
exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely 
consistently with constant rate events. Drawing any conclusions about the durability of the 
treatment effect on all exacerbations from this digitised plot, which shows only first exacerbations, 
is methodologically incorrect. 
Consider a repeating event endpoint (such as exacerbations) in two treatment groups, A (low 
constant rate) and B (high constant rate). Initially the gradient of the survival curve for the first event 
for treatment B (high rate) will be very steep, because all patients are “at risk” of an event. As fewer 
and fewer patients are left available to have a first event, the gradient will necessarily diminish. The 
gradient of the survival curve for the first event for treatment A (low rate) will eventually become 
steeper. Eventually the two survival curves for time to first event will converge despite event rates 
being different in both arms, as illustrated in the Figure which is described by the equations below. 
Suppose that in treatment arm A events occur at a constant annual rate of 1.0, and in treatment arm 
B events occur with a constant annual rate of 1.5. The exponential survival functions (i.e. the 
functions that describe survival for events with constant hazard rates) are given by:  
𝑆𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝐴(𝑡) = 1 − exp(−t) 
𝑆𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝐵(𝑡) = 1 − exp(−1.5t) 
Where t is the time in years [3]. The resulting survival curves can be plotted and it is also possible to 
differentiate with respect to t, to obtain the gradient  𝐺(𝑡) = S ′(t) of the survival curves which 
corresponds to the digitised plot presented by Suissa and Ariel. 
𝐺𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝐴(𝑡) = exp(−t) 
𝐺𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝐵(𝑡) = 1.5 exp(−1.5t) 
These survival curves converge, and the gradient of both curves start to diminish, with the gradient 
functions crossing exactly as shown in the real data (Figure). It is important to understand this 
phenomenon occurs for constant rate events, and therefore its presence should not be taken as 
evidence that the rates are not constant.  
This can be understood in the following way: the cumulative incidence or survival curve only 
describes the first event experienced by each patient. If treatment A consistently reduces the rate of 
events, then these first events will be delayed but they will still occur. While patients on treatment A 
are experiencing their first events there are simply fewer patients on the treatment B arm who are 
still “at risk” of a first event, these events having already occurred. By this point patients on 
treatment B are having second or third events, which are not captured by a time to first event 
analysis, thus the rate of their first events has diminished. 
This illustrates that conclusions about the durability of the treatment effect over time cannot be 
based on analyses restricted to looking at only the first event of many. To imply that the treatment 
effect diminishes because one survival curve catches up with another is inappropriate and risks 
propagating incorrect information, which could lead to harm to patients if treatment is withdrawn or 
not used. 
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Figure legend 
Figure. Hypothetical example of a cumulative event plot, survival curve and gradient of survival 
curve presented on the same data. 
  
 
